These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 38594892)

  • 1. Current usage of pembrolizumab in triple negative breast cancer (TNBC).
    O'Rourke H; Hart C; De Boer RH
    Expert Rev Anticancer Ther; 2024 May; 24(5):253-261. PubMed ID: 38594892
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pembrolizumab in the preoperative setting of triple-negative breast cancer: safety and efficacy.
    Barroso-Sousa R; Tolaney SM
    Expert Rev Anticancer Ther; 2020 Nov; 20(11):923-930. PubMed ID: 32930616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pembrolizumab and atezolizumab in triple-negative breast cancer.
    Kwapisz D
    Cancer Immunol Immunother; 2021 Mar; 70(3):607-617. PubMed ID: 33015734
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial.
    Winer EP; Lipatov O; Im SA; Goncalves A; Muñoz-Couselo E; Lee KS; Schmid P; Tamura K; Testa L; Witzel I; Ohtani S; Turner N; Zambelli S; Harbeck N; Andre F; Dent R; Zhou X; Karantza V; Mejia J; Cortes J;
    Lancet Oncol; 2021 Apr; 22(4):499-511. PubMed ID: 33676601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atezolizumab and pembrolizumab in triple-negative breast cancer: a meta-analysis.
    Latif F; Bint Abdul Jabbar H; Malik H; Sadaf H; Sarfraz A; Sarfraz Z; Cherrez-Ojeda I
    Expert Rev Anticancer Ther; 2022 Feb; 22(2):229-235. PubMed ID: 34949142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522.
    Pusztai L; Denkert C; O'Shaughnessy J; Cortes J; Dent R; McArthur H; Kümmel S; Bergh J; Park YH; Hui R; Harbeck N; Takahashi M; Untch M; Fasching PA; Cardoso F; Zhu Y; Pan W; Tryfonidis K; Schmid P
    Ann Oncol; 2024 May; 35(5):429-436. PubMed ID: 38369015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biomarkers of Immune Checkpoint Blockade Response in Triple-Negative Breast Cancer.
    Isaacs J; Anders C; McArthur H; Force J
    Curr Treat Options Oncol; 2021 Mar; 22(5):38. PubMed ID: 33743085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune checkpoint inhibition in early-stage triple-negative breast cancer.
    Varma R; Wright M; Abraham J; Kruse M
    Expert Rev Anticancer Ther; 2022 Nov; 22(11):1225-1238. PubMed ID: 36278877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.
    Cortes J; Cescon DW; Rugo HS; Nowecki Z; Im SA; Yusof MM; Gallardo C; Lipatov O; Barrios CH; Holgado E; Iwata H; Masuda N; Otero MT; Gokmen E; Loi S; Guo Z; Zhao J; Aktan G; Karantza V; Schmid P;
    Lancet; 2020 Dec; 396(10265):1817-1828. PubMed ID: 33278935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Checkpoint inhibitors in triple-negative breast cancer (TNBC): Where to go from here.
    Kwa MJ; Adams S
    Cancer; 2018 May; 124(10):2086-2103. PubMed ID: 29424936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pembrolizumab plus chemotherapy for first-line treatment of advanced triple-negative breast cancer.
    Haiderali A; Huang M; Pan W; Akers KG; Maciel D; Frederickson AM
    Future Oncol; 2024; 20(22):1587-1600. PubMed ID: 38597713
    [No Abstract]   [Full Text] [Related]  

  • 12. The anti-cancer immune response in breast cancer: current and emerging biomarkers and treatments.
    Rayson VC; Harris MA; Savas P; Hun ML; Virassamy B; Salgado R; Loi S
    Trends Cancer; 2024 Jun; 10(6):490-506. PubMed ID: 38521654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of Immunotherapy in Breast Cancer.
    Jacob SL; Huppert LA; Rugo HS
    JCO Oncol Pract; 2023 Apr; 19(4):167-179. PubMed ID: 36608303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of immune checkpoint inhibition in triple negative breast cancer.
    Tarekegn K; Keskinkilic M; Kristoff TJ; Evans ST; Kalinsky K
    Expert Rev Anticancer Ther; 2023; 23(10):1095-1106. PubMed ID: 37771270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progress in immune checkpoint inhibition in early-stage triple-negative breast cancer.
    Mohamed A; Kruse M; Tran J
    Expert Rev Anticancer Ther; 2023; 23(10):1071-1084. PubMed ID: 37747062
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of patients with early-stage triple-negative breast cancer following pembrolizumab-based neoadjuvant therapy: What are the evidences?
    Bonadio RC; Tarantino P; Testa L; Punie K; Pernas S; Barrios C; Curigliano G; Tolaney SM; Barroso-Sousa R
    Cancer Treat Rev; 2022 Nov; 110():102459. PubMed ID: 35998514
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune checkpoint inhibitors for triple-negative breast cancer: From immunological mechanisms to clinical evidence.
    Farshbafnadi M; Pastaki Khoshbin A; Rezaei N
    Int Immunopharmacol; 2021 Sep; 98():107876. PubMed ID: 34146865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The evolving role of immune checkpoint inhibitors in the treatment of triple-negative breast cancer.
    Steiner M; Tan AR
    Clin Adv Hematol Oncol; 2021 May; 19(5):305-315. PubMed ID: 33989278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The emerging role of immune checkpoint inhibitors for the treatment of breast cancer.
    Howard FM; Villamar D; He G; Pearson AT; Nanda R
    Expert Opin Investig Drugs; 2022 Jun; 31(6):531-548. PubMed ID: 34569400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancer.
    Agostinetto E; Losurdo A; Nader-Marta G; Santoro A; Punie K; Barroso R; Popovic L; Solinas C; Kok M; de Azambuja E; Lambertini M
    Expert Opin Investig Drugs; 2022 Jun; 31(6):567-591. PubMed ID: 35240902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.